Meta-analysis for cyclin E in lung cancer survival

Clinica Chimica Acta

Volumn 413, Issue 7-8, 2012, Pages 663-668

  Huang, Li Nian ^a   Wang, Dong Sheng ^a,b   Chen, Yu Qing ^a   Li, Wei ^a   Hu, Feng Dan ^c   Gong, Bei Lei ^a   Zhao, Cheng Ling ^a   Jia, Wei ^a  

^a BENGBU MEDICAL COLLEGE   (China)

^b ANHUI PROVINCIAL HOSPITAL   (China)

^c Wuhe County Hospital   (China)

Author keywords

Cyclin E; Lung cancer; Meta analysis; Prognosis

Indexed keywords

CYCLIN E;

ADENOCARCINOMA; CANCER RISK; CANCER SURVIVAL; DISEASE ASSOCIATION; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; HISTOPATHOLOGY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; META ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SENSITIVITY ANALYSIS; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW;

CYCLIN E; HUMANS; LUNG NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84862782087     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.12.020     Document Type: Review

References (36)

1. Boyle P., Dresler C. Preventing the lung cancer epidemic. Ann Oncol 2005 Oct, 16(10):1565-1566.
2. Witschi H. A short history of lung cancer. Toxicol Sci 2001, 64(1):4-6.
3. Esposito L., Conti D., Ailavajhala R., Khalil N., Giordano A. Lung cancer: are we up to the challenge?. Curr Genomics 2010, 11(7):513-518.
4. Cox G., Jones J.L., Andi A., Waller D.A., O'Byrne A biological staging model for operable non-small cell lung cancer. Thorax 2001, 56:561-566.
5. Tong J., Sun X., Cheng H., Zhao D., Ma J., Zhen Q., et al. Expression of p16 in non-small cell lung cancer and its prognosis significance: a meta-analysis of published literatures. Lung Cancer 2011, 74:155-163.
6. Martin B., Paesmans M., Berghmans T., Branle F., Ghisdal L., Mascaux C., et al. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2003, 89(1):55-64.
7. Martin B., Paesmans M., Mascaux C., Berghmans T., Lothaire P., Meert A.P., et al. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 2004, 91(12):2018-2025.
8. Zhuang Y., Yin H.T., Yin X.L., Wang J., Zhang D.P. High p27 expression is associated with a better prognosis in East Asian non-small cell lung cancer patients. Clin Chim Acta 2011, 412(23-24):2228-2231.
9. Pines J., Hunter T. Isolation of a human cyclin cDNA: evidence for cyclin mRNA and protein regulation in the cell cycle for interaction with p34cdc2. Cell 1989, 58:833-846.
10. Keyomarsi K., O'Leary N., Molnar G., Lees E., Fingert H.J., Pardee A.B. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 1994, 54:380-385.
11. Dutta A., Chandra R., Leiter L.M., Lester S. Cyclins as markers of tumor proliferation: immunohistochemical studies in breast cancer. Proc Natl Acad Sci U S A 1995, 92:5386-5390.
12. Kitahara K., Yasui W., Kuniyasu H., Yokozaki H., Akama Y., Yunotani S., et al. Concurrent amplification of cyclin E and cdk2 genes in colorectal carcinomas. Int J Cancer 1995, 62:25-28.
13. Del Pizzo J., Borkowski A., Jacobs S.C., Kyprianou N. Loss of cell cycle regulators in p27 (Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am J Pathol 1999, 155:1129-1136.
14. Bito T., Ueda M., Ito A., Ichihashi M. Less expression of cyclin E in cutaneous squamous cell carcinomas than in benign and premalignant keratinocytic lesions. J Cutan Pathol 1997, 24:305-308.
15. Dobashi Y., Shoji M., Jiang S.X., Kobayashi M., Kawakubo Y., Kameya T. Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. Am J Pathol 1998 Sep, 153(3):963-972.
16. Fukuse T., Hirata T., Naiki H., Hitomi S., Wada H. Prognostic significance of cyclin E over-expression in resected non-small cell lung cancer. Cancer Res 2000, 60(2):242-244. 15.
17. Mishina T., Dosaka-Akita H., Hommura F., Nishi M., Kojima T., Ogura S., et al. Cyclin E expression, a potential prognostic marker for non-small cell lung cancers. Clin Cancer Res 2000, 6(1):11-16.
18. Ikehara M., Oshita F., Ito H., Ohgane N., Suzuki R., Saito H., et al. Expression of cyclin D1 but not of cyclin E is an indicator of poor prognosis in small adenocarcinomas of the lung. Oncol Rep 2003, 10(1):137-139.
19. Parmar M.K., Torri V., Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998, 17:2815-2834.
20. Yusuf S., Peto R., Lewis J., Collins R., Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985, 27:335-371.
21. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
22. Banerjee I. Relationship between paraoxonase 1 (PON1) gene polymorphisms and susceptibility of stroke: a meta-analysis. Eur J Epidemiol 2010, 25(7):449-458.
23. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
24. Egger M., Davey Smith G., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
25. Anton R.C., Coffey D.M., Gondo M.M., Stephenson M.A., Brown R.W., Cagle P.T. The expression of cyclins D1 and E in predicting short-term survival in squamous cell carcinoma of the lung. Mod Pathol 2000, 13(11):1167-1172.
26. Müller-Tidow C., Metzger R., Kügler K., Diederichs S., Idos G., Thomas M., et al. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res 2001, 61(2):647-653.
27. Dosaka-Akita H., Hommura F., Mishina T., Ogura S., Shimizu M., Katoh H., et al. A risk-stratification model of non-small cell lung cancers using cyclin E, Ki-67, and ras p21: different roles of G1 cyclins in cell proliferation and prognosis. Cancer Res 2001, 61(6):2500-2504.
28. Hayashi H., Ogawa N., Ishiwa N., Yazawa T., Inayama Y., Ito T., et al. High cyclin E and low p27/Kip1 expressions are potentially poor prognostic factors in lung adenocarcinoma patients. Lung Cancer 2001, 34(1):59-65.
29. Gao A.F., Wang L.P., Qiu X.S. Expression of p27, cyclin E and their correlation with prognosis of NSCLC. Chin J Clin Oncol Rehabil 2001, 6:53-56.
30. Takahashi S., Kamata Y., Tamo W., Koyanagi M., Hatanaka R., Yamada Y., et al. Relationship between postoperative recurrence and expression of cyclin E, p27, and Ki-67 in non-small cell lung cancer without lymph node metastases. Int J Clin Oncol 2002, 7(6):349-355.
31. Dobashi Y., Jiang S.X., Shoji M., Morinaga S., Kameya T. Diversity in expression and prognostic significance of G1/S cyclins in human primary lung carcinomas. J Pathol 2003, 199(2):208-220.
32. Shou Y.N., Liu D., Ping Y.L., Gong Y.B., Maeda J., Yoshida K., et al. Expression of p57/kip2 and cyclin E in non-small cell lung cancer and their association with pathological factors of prognosis. Chin J coal ind med 2007, 6:636-638.
33. Yoo J., Jung J.H., Lee M.A., Seo K.J., Shim B.Y., Kim S.H., et al. Immunohistochemical analysis of non-small cell lung cancer: correlation with clinical parameters and prognosis. J Korean Med Sci 2007, 22(2):318-325.
34. Filipits M., Pirker R., Dunant A., Lantuejoul S., Schmid K., Huynh A., et al. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol 2007, 25:2735-2740.
35. Kosacka M., Piesiak P., Porebska I., Korzeniewska A., Dyla T., Jankowska R. Cyclin A and cyclin E expression in resected non-small cell lung cancer stage I-IIIA. In Vivo 2009, 23(4):519-525.
36. Nakamura H., Kawasaki N., Taguchi M., Kabasawa K. Survival impact of epidermal growth factor receptor over-expression in patients with non-small cell lung cancer: a meta-analysis. Thorax 2006, 61(2):140-145.